PUBLISHER: The Business Research Company | PRODUCT CODE: 1942825
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942825
Enzyme immunoassay is a highly sensitive laboratory technique that utilizes antibodies conjugated with enzymes to specifically identify and quantify target molecules such as proteins, hormones, or infectious agents within a sample. The method is based on an enzymatic reaction that generates a detectable signal-often a color change-which correlates directly with the concentration of the analyte, enabling accurate diagnostic or research analysis.
The primary product types in enzyme immunoassay include reagents and kits, analyzers or instruments, and software and services. Reagents and kits consist of chemical substances or pre-packaged sets of chemicals used in laboratory and clinical testing to detect, measure, or process other substances. These products accommodate various specimen types, such as blood, saliva, urine, and others, and support a wide array of applications, including therapeutic drug monitoring, oncology, cardiology, endocrinology, infectious disease detection, autoimmune disease testing, and more. They serve a broad range of end users, including hospitals, blood banks, clinical laboratories, pharmaceutical and biotechnology companies, academic research centers, and other institutions.
Tariffs are impacting the enzyme immunoassay market by increasing costs of imported reagents, kits, and analyzers, impacting production and procurement expenses. Segments such as fully automated analyzers and specialized reagents are most affected, particularly in Asia-Pacific regions like China and India, which serve as major manufacturing hubs. While tariffs have introduced supply chain challenges and price pressures, they have also encouraged local manufacturing, innovation in assay kits, and development of domestic production capabilities.
The enzyme immunoassay market research report is one of a series of new reports from The Business Research Company that provides enzyme immunoassay market statistics, including enzyme immunoassay industry global market size, regional shares, competitors with a enzyme immunoassay market share, detailed enzyme immunoassay market segments, market trends and opportunities, and any further data you may need to thrive in the enzyme immunoassay industry. This enzyme immunoassay market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The enzyme immunoassay market size has grown strongly in recent years. It will grow from $21.5 billion in 2025 to $23.09 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to limited availability of automated eia systems, reliance on manual microplate readers, growing clinical laboratory infrastructure, increasing prevalence of chronic and infectious diseases, adoption of conventional reagents and kits.
The enzyme immunoassay market size is expected to see strong growth in the next few years. It will grow to $30.37 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to development of fully automated eia analyzers, expansion of personalized medicine and precision diagnostics, increasing integration of laboratory information systems, rising adoption of software and data analysis tools, growing demand from academic and research institutions. Major trends in the forecast period include rising adoption of automated eia analyzers, growth in therapeutic drug monitoring applications, increasing use of multiplex testing and high-throughput assays, expansion of oncology and infectious disease testing, enhanced focus on laboratory data integration and workflow efficiency.
The increasing prevalence of infectious diseases is anticipated to drive the growth of the enzyme immunoassay market. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can be transmitted between individuals. The burden of these diseases is growing due to rising antimicrobial resistance, which complicates treatment, extends recovery times, raises healthcare costs, and leads to increased mortality. Enzyme immunoassays are essential tools for diagnosing infectious diseases, offering sensitive and specific detection of antigens or antibodies in patient samples. This facilitates early diagnosis, effective monitoring, and timely treatment for conditions such as HIV, hepatitis, and influenza. For example, in April 2025, the Minnesota Department of Health, a US-based government agency, reported that the proportion of HIV cases among males aged 35 to 39 increased from 10% in 2023 to 17% in 2024, reflecting a significant rise in this demographic. As a result, the increasing burden of infectious diseases is contributing to the expansion of the enzyme immunoassay market.
Leading companies in the enzyme immunoassay market are prioritizing the development of advanced solutions, such as fully automated enzyme immunoassays, to boost diagnostic accuracy, reduce human error, and improve workflow efficiency in clinical laboratories. Fully automated enzyme immunoassays streamline the entire testing process, enhancing the speed, precision, and reliability of laboratory diagnostics. For instance, in July 2024, Fujirebio Holdings Inc., a Japan-based in vitro diagnostics company, introduced the fully automated Lumipulse G GFAP assay for research use only (RUO), expanding its neuro-biomarker product line. This chemiluminescent enzyme immunoassay measures glial fibrillary acidic protein (GFAP) levels in human plasma and serum using the LUMIPULSE G platform, delivering results within 35 minutes. GFAP is an astrocytic biomarker associated with neurological conditions such as multiple sclerosis, Alzheimer's and Parkinson's diseases, stroke, and traumatic brain injury. This new assay complements Fujirebio's neurodegenerative disease portfolio, which already includes markers like NfL, pTau217, and sTREM2, supporting comprehensive profiling on a single automated platform.
In January 2025, Medix Biochemica, a Finland-based supplier of raw materials for in vitro diagnostics, acquired CANDOR Bioscience GmbH for an undisclosed sum. This acquisition is aimed at strengthening Medix Biochemica's position as a leading global provider in the IVD industry by expanding its portfolio with CANDOR's specialized expertise in high-performance blockers and assay optimization reagents. These technologies support improved performance in enzyme immunoassays and enable more robust diagnostic test development. CANDOR Bioscience GmbH is a Germany-based biotechnology company that focuses on optimizing immunoassay systems, including enzyme immunoassays and ELISA development.
Major companies operating in the enzyme immunoassay market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Merck KGaA, Siemens Healthineers AG, Becton Dickinson and Company (BD), PerkinElmer Inc., BioMerieux SA, Bio-Rad Laboratories Inc., Diasorin S.p.A., Bio-Techne Corporation, Quidel Corporation, Promega Corporation, Abcam plc, BioLegend Inc., Helena Laboratories Corporation, Cayman Chemical Company, Enzo Life Sciences Inc., RayBiotech Inc., MyBioSource Inc., Boster Biological Technology, Hycult Biotech, Calbiotech Inc.
North America was the largest region in the enzyme immunoassay market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the enzyme immunoassay market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the enzyme immunoassay market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The enzyme immunoassay market consists of sales of enzyme-labeled antibodies, sample diluents, blocking reagents, microplate readers, ELISA test kits, robotic liquid handling systems, and plate washers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Enzyme Immunoassay Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses enzyme immunoassay market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for enzyme immunoassay ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The enzyme immunoassay market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.